Skip to content
Open access

A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency

Oct 2026 · bioRxiv · 0 citations · 47 references
Medicine Biology

TL;DR

T4IL15Δ is engineered, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation, and provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.

Abstract

Antiretroviral therapy suppresses HIV-1 replication but cannot eliminate the latent viral reservoir persisting in memory CD4 T cells. Existing latency reversal candidates have yet to achieve robust viral reactivation at tolerable doses. We engineered T4IL15Δ, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation. T4IL15Δ reactivated latent virus in 94% (48/51) of clinical samples ex vivo, 75% (15/20) of administrations in HIV-1-infected and ART-suppressed humanized mice, and 100% (6/6) of SIV-infected and ART-suppressed rhesus macaques at doses well tolerated. We also found that off-target stimulation of non-CD4 cells hindered HIV-1 reactivation ex vivo. T4IL15Δ provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.

Read PDF

Similar papers

Review Open access Nov 2026

Harnessing Natural Killer Cells for HIV-1 Treatment and Vaccine Development: A Review

Human immunodeficiency virus type 1 (HIV-1) causes progressive immune dysfunction and, if untreated, can lead to acquired immunodeficiency syndrome (AIDS). Although combination antiretroviral therapy (cART) effectively suppresses viral replication and has substantially improved outcomes for people living with HIV (PLWH...

Christopher Nieva, Emma Lai, M. Sarkandi et al. · 0 citations
Open access Oct 2026

SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion

Antiretroviral therapy (ART) suppresses viraemia in people with human immunodeficiency virus (HIV), but HIV provirus persists indefinitely in CD4-expressing cells. Cells containing active provirus express viral proteins and have been successfully targeted using broadly neutralizing antibodies (bnAbs). In contrast, cell...

J. Deere, David Merriam, K. Machmach et al. · 0 citations
Open access Oct 2026

Viral Genetic Traits of Durable Control in Dual Immunotherapy-treated SHIV-infected Rhesus Macaques

The interruption of antiretroviral therapy (ART) in HIV-1 infected individuals leads to rapid viral rebound, highlighting the persistent challenge of eradicating HIV-1 reservoirs. Our previous study demonstrated that combined administration of N-803 (Anktiva) combined with the broadly neutralizing antibodies (bNAbs),...

M. Marichannegowda, S. Lim, C. Fennessey et al. · 0 citations
Open access Oct 2026

Cell-based therapy for HIV brain reservoirs: glial progenitors delivering broadly neutralizing antibodies

Abstract Objective Despite the success of combination antiretroviral therapy (cART) in suppressing HIV replication, viral reservoirs persist in a latent state in resting memory CD4+ T-cells, lymphoid tissue and spleen, as well as in glia within the central nervous system (CNS), necessitating lifelong treatment. Persist...

Lorissa I. McDougall, A. Abbasi, Mohammad M. Sajadi et al. · 0 citations
Open access Oct 2026

Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans

Inducing a broadly neutralizing antibody (bnAb) response is a key goal of HIV-1 vaccine development. Despite significant progress, it is unknown whether vaccine-primed B cells can be reactivated and matured to secrete bona fide bnAbs. In the IAVI C107/C110 single-arm, open-label human trial, VRC01-class memory B cells...

T. Caniels, Madhu S. Prabhakaran, S. Agrawal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.